SARS-CoV-2 Spike RBD Neutralizing Antibody, monoclonal

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293) . This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 ug/mL using SARS-CoV-2 Inhibitor Screening Kit .Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

For long term storage, the product should be stored at lyophilized state at -20˚ C or lower..Please avoid repeated freeze-thaw cycles.This product is stable after storage at:.-20 to -70˚ C for 12 months in lyophilized state from date of receipt; .-70˚ C for 3 months under sterile conditions after reconstitution.

This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.